A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516612-16-00

Acronym

LOLA trial

Enrollment

Registered

2024-11-04

Start date

2020-06-17

Completion date

Unknown

Last updated

2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET)

Brief summary

Safety and tolerabilitity in terms of the rate (%) of patients experiencing grade 3-5 toxicities according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0

Detailed description

Secondary endpoints include Progression Free Survival (PFS) and Overall Survival (OS)

Interventions

DRUGCABOZANTINIB

DRUGLANREOTIDE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Safety and tolerabilitity in terms of the rate (%) of patients experiencing grade 3-5 toxicities according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0	—

Secondary

Measure	Time frame
Secondary endpoints include Progression Free Survival (PFS) and Overall Survival (OS)	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026